Menu
Not yet recruiting NCT07674680

Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women

Early Phase I Interventional Women Aging Menopause

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Placebo, Gemtesa.
Who it may be relevant to
Registry conditions: Women, Aging, Menopause. Basic parameters: 18 years — 70 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.

Interventions

  • Drug Placebo
    Participants will receive a placebo in pill form.
  • Drug Gemtesa
    Participants will receive oral gemtesa (75 mg).

Primary outcome measures

  • Blood flow [Time frame: Change from baseline to minute 2.]

Eligibility criteria

Inclusion criteria

  • Healthy women,
  • Assigned female at birth,
  • 18-70 years of age,
  • Body mass index <18 or ≥30 kg/m2,

Exclusion criteria

  • Assigned male at birth,
  • Pregnancy,
  • Breastfeeding,
  • History of hormone replacement therapy, chemical menopause, or oophor-ectomy
  • Polycystic ovarian syndrome or Primary ovarian insufficiency,
  • Current smoking/Nicotine use,
  • Blood pressure ≥140/90 mmHg,
  • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,
  • Nerve/neurologic disease,
  • Cardiovascular, hepatic, renal, respiratory disease,
  • Hypersensitivity to nitroglycerin,
  • Diabetes,
  • Communication barriers,

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Single blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • University of Missouri — Columbia

Identifiers

NCT: NCT07674680 · 2135088

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗